A Prospective Interventional Study to Find the Effectivity of Razumab by Measuring Macular Oedema before and after Intravitreal Injection

Abstract Aim: To test effectiveness (before and after) of a single dose of intravitreal Razumab in treatment naïve patients with macular oedema due to diabetic retinopathy or retinal vein occlusion. Introduction: Razumab® is the world’s first biosimilar to Ranibizumab approved in India by DCGI in 2015. We aim to study the efficacy of Razumab, in reducing macular oedema due to diabetic retinopathy (DR) and retinal vein occlusion based on optical coherence tomography (Non invasive imaging) in a medical college hospital over 1 year. Materials and Methods: A prospective interventional (before and after) study conducted on treatment naïve patients diagnosed with macular oedema secondary to DR or retinal vein occlusion with best-corrected visual acuity (BCVA) according to LogMAR chart ≤0.2 and central retinal thickness (CRT) by OCT ≥315 μ. Inj Razumab 0.5 mg in 0.05 ml was given intravitreally. The patient was followed up after 1 week and 4 weeks. The BCVA and OCT were repeated 1 month postoperatively. Results: 68% of patients showed clinical improvement at the end of 1 month follow-up. Paired samples test showed a statistically significant P value of 0.0001 for pre- and postinjection BCVA at the end of 1 month. A statistically significant P value of 0.0001 was obtained for pre- and postinjection CRT at the end of 1 month. Conclusion: This study demonstrates the short-term efficacy of action of a single dose of Razumab and is predictive of its success as an effective treatment option for retinal vascular diseases in developing countries.